Population Study to Prevent or Treat Multiple Myeloma

The iStopMM study of the has been described as one of most important events in modern day myeloma care. It stands for Iceland Screens, Treats, or Prevents Multiple Myeloma and is in fact a nation wide screening study, under the auspices of Department of Hematology at Landspítali University Hospital, Iceland.

Multiple Myeloma is a cancer in plasma cells in the bone marrow. A precursor to Multiple Myeloma is MGUS and that is what iStopMM is screening for in Iceland. iStopMM is part of the International Myeloma Foundation's Black Swan Research Initiative.

Dr. Sigurdur Kristinsson of the University of Iceland explains that as port of the iStopMM study, 140,000 Icelanders over the age of 40 will have their blood samples tested for the precursor to multiple myeloma, MGUS or monoclonal gammopathy of undetermined significance. If they test for MGUS, they are given the option to take part in a randomized clinical trial to treat or prevent the progression of MM. 

Get in touch

For further information on the benefits of establishing a business in Iceland please feel free to contact us.


Iceland focuses on a favorable business environment, including low corporate tax, availability of land and green energy at competitive prices and efficiency within European legislative framework. Generous support for R&D.

Why Iceland

Along with having one of the lowest corporate tax rate in Europe, Iceland has a highly educated workforce which is ranked among the highest in the world, offers competitively priced renewable energy with an advanced infrastructure making Iceland an ideal location for investors